Milane Tracy, Vuillerme Nicolas, Petit Pascal, Warmerdam Elke, Romijnders Robbin, Bianchini Edoardo, Maetzler Walter, Hansen Clint
Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Germany.
Univ. Grenoble Alpes, AGEIS, Grenoble, 38000, France.
BMC Neurol. 2025 Sep 9;25(1):379. doi: 10.1186/s12883-025-04321-2.
Parkinson's disease (PD) is characterized by motor symptoms altering gait domains such as slow walking speed, reduced step and stride length, and increased double support time. Gait disturbances occur in the early, mild to moderate, and advanced stages of the disease in both backward walking (BW) and forward walking (FW), but are more pronounced in BW. At this point, however, no information is available about BW performance and disease stages specified using the Hoehn and Yahr (H&Y) scale. The objectives of this study were to examine the link between clinical scores and gait parameters in PD, and to assess gait parameters in both FW and BW among PD patients in early disease stages (H&Y: 1-2) and advanced disease stages (H&Y: 3-4), as well as among PD patients with mild and moderate disease severity as per the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III).
Spatiotemporal gait parameters were analyzed during FW and BW over a 5-meter walkway at a comfortable speed using 3D motion capture. Correlations and regressions between clinical scores and gait parameters were examined. Wilcoxon Mann-Whitney rank sum tests were used to compare PD patients in early and advanced disease stages and assess differences in gait parameters for both FW and BW conditions.
The study included a total of 25 PD patients (aged 65 ± 9 years), among whom 10 were in the H&Y stages 1-2 and 15 in stages 3-4. All participants were evaluated with the MDS-UPDRS III, with 17 having a total score ≤ 32 (mild impairment and disability) and 8 having a total score > 32 (moderate impairment and disability). During BW, PD patients with H&Y stages 1-2 had significantly (p < 0.05) longer step lengths, stride lengths, and a higher walk ratio compared to those with H&Y stage 3-4. Regardless of the walking condition, no difference was found between PD patients with a MDS-UPDRS III total score ≤ 32 and patients with a MDS-UPDRS III total score > 32.
The study demonstrates that individuals with PD in H&Y stages 3-4 exhibit compromised FW and BW abilities in comparison to those in stages 1-2. Notably, the disparities are more prominent in the realm of backward walking. These findings substantiate the existence of distinct gait patterns between the early and advanced stages of the disease, with the variations being particularly accentuated in the context of backward walking.
Taken together, our results suggest that backward walking may hold greater clinical utility in assessing and managing PD patients.
The research procedure was approved by the ethical committee of the Medical Faculty of Kiel University (D438/18). The study is registered in the German Clinical Trials Register on 20,200,904 (DRKS00022998).
帕金森病(PD)的特征是运动症状会改变步态特征,如步行速度减慢、步幅和步长减小以及双支撑时间增加。步态障碍在疾病的早期、轻度至中度以及晚期阶段的向后行走(BW)和向前行走(FW)中均会出现,但在向后行走中更为明显。然而,目前尚无关于使用霍恩和雅尔(H&Y)量表确定的向后行走表现与疾病阶段的信息。本研究的目的是检查PD患者临床评分与步态参数之间的联系,并评估疾病早期阶段(H&Y:1 - 2)和晚期阶段(H&Y:3 - 4)以及根据运动障碍协会统一帕金森病评定量表第三部分(MDS - UPDRS III)评定为轻度和中度疾病严重程度的PD患者在向前行走和向后行走中的步态参数。
使用3D运动捕捉技术,以舒适的速度在5米长的通道上对向前行走和向后行走过程中的时空步态参数进行分析。检查临床评分与步态参数之间的相关性和回归关系。采用威尔科克森 - 曼 - 惠特尼秩和检验来比较疾病早期和晚期的PD患者,并评估向前行走和向后行走条件下步态参数的差异。
该研究共纳入25例PD患者(年龄65±9岁),其中10例处于H&Y 1 - 2期,15例处于3 - 4期。所有参与者均接受了MDS - UPDRS III评估,其中17例总分≤32(轻度损伤和残疾),8例总分>32(中度损伤和残疾)。在向后行走过程中,与H&Y 3 - 4期患者相比,H&Y 1 - 2期的PD患者步长、步幅显著更长(p < 0.05),步幅比更高。无论行走条件如何,MDS - UPDRS III总分≤32的PD患者与总分>32的患者之间均未发现差异。
该研究表明,与1 - 2期患者相比,H&Y 3 - 4期的PD患者向前行走和向后行走能力受损。值得注意的是,这些差异在向后行走领域更为突出。这些发现证实了疾病早期和晚期存在不同的步态模式,且在向后行走时差异尤为明显。
综上所述,我们的结果表明,向后行走在评估和管理PD患者方面可能具有更大的临床应用价值。
该研究程序已获得基尔大学医学院伦理委员会批准(D438/18)。该研究于2020年9月4日在德国临床试验注册中心注册(DRKS00022998)。